• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B.
【24h】

Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B.

机译：定量乙型肝炎表面抗原，乙型肝炎电子抗原和乙型肝炎病毒DNA水平之间的比较，以预测乙型肝炎电子抗原阳性的慢性乙型肝炎对聚乙二醇化干扰素-α-2b治疗的病毒学应答。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: The aim of this study was to compare the clinical applicability of quantitative serum hepatitis B surface antigen (HBsAg), hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA for predicting virological response (VR) to pegylated interferon (PEG-IFN) therapy. Methods: Thirty HBeAg-positive chronic hepatitis B patients who received PEG-IFN-alpha-2b for 48 weeks were enrolled. Quantitative HBsAg, HBeAg and HBV DNA were measured before, during and after the therapy. Paired liver biopsies were performed before and after treatment for covalently closed circular (ccc)DNA and intrahepatic HBV DNA analysis. Results: VR at 48 weeks post-treatment, defined as HBeAg seroconversion and HBV DNA less than 10 000 copies/mL was achieved in 10 (33.3%) patients. Responders had significantly lower baseline HBsAg, HBeAg, cccDNA and intrahepatic HBV DNA levels than non-responders. Baseline and reduced levels of log(10) HBsAg and log(10) HBeAg correlated well with those of log(10) cccDNA and log(10) total intrahepatic HBV DNA. Responders showed consistent decrease in serum HBsAg, HBeAg and HBV DNA levels during therapy. HBeAg level of 2.0 log(10) sample to cut-off ratio at week 24 on therapy provided the best prediction of sustained virological response, with sensitivity and negative predictive values of 85% and 92%, respectively. One patient (3.3%) who cleared HBsAg at follow up exhibited a more rapid decline in serum HBsAg during therapy than those who developed VR without HBsAg clearance. Conclusion: Quantitative measurement of serum HBeAg during therapy may be superior to serum HBsAg and HBV DNA as a prediction of HBeAg seroconversion. Kinetics of HBsAg levels on therapy may help predict HBsAg clearance after treatment.
机译：目的：本研究的目的是比较定量的血清乙型肝炎表面抗原（HBsAg），乙型肝炎电子抗原（HBeAg）和乙型肝炎病毒（HBV）DNA的临床适用性，以预测对聚乙二醇化干扰素的病毒学应答（VR） （PEG-IFN）治疗。方法：纳入30名接受PEG-IFN-α-2b治疗48周的HBeAg阳性慢性乙型肝炎患者。在治疗前，治疗中和治疗后对HBsAg，HBeAg和HBV DNA进行定量测定。在治疗前和治疗后进行配对肝活检，以进行共价闭合环状（ccc）DNA和肝内HBV DNA分析。结果：治疗后48周的VR定义为HBeAg血清转化和HBV DNA低于10000拷贝/ mL的患者达到10（33.3％）。应答者的基线HBsAg，HBeAg，cccDNA和肝内HBV DNA水平显着低于非应答者。 log（10）HBsAg和log（10）HBeAg的基线水平和降低水平与log（10）cccDNA和log（10）总肝内HBV DNA的相关性很好。应答者在治疗期间血清HBsAg，HBeAg和HBV DNA水平持续下降。在治疗第24周时，HBeAg水平为2.0 log（10）样本与截留值之比可提供最佳的持续病毒学应答预测，其敏感性和阴性预测值分别为85％和92％。随访时清除HBsAg的一名患者（3.3％）在治疗期间比未清除HBsAg的VR患者表现出更快的血清HBsAg下降。结论：治疗期间对血清HBeAg的定量检测可能优于血清HBsAg和HBV DNA，可预测HBeAg血清转化。治疗后HBsAg水平的动力学可能有助于预测治疗后的HBsAg清除率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号